Markets:

Overview

News

Currencies

International

Treasuries

AstraZeneca PLC - American Depositary Shares (NQ:AZN)

90.17 -0.35 (-0.39%)

Streaming Delayed Price Updated: 4:00 PM EST, Dec 2, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about AstraZeneca PLC - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9

...

74 75 Next >

China-Tied Biotechs Zai Labs, BeOne Plunge On Rumored Executive Order ↗

September 10, 2025

Zai Labs and BeOne Medicines plummeted Wednesday on reports an executive order could reduce access to China-developed drugs.

Via Investor's Business Daily

Topics Government

FDA Expands Approval For AstraZeneca's Drug For Pediatric Patients With Rare Type Of Cancer ↗

September 10, 2025

The FDA approved AstraZeneca's Koselugo for children 1+ with NF1 and inoperable nerve tumors, expanding treatment options with an established safe dose.

Via Benzinga

Trump's Biotech Playbook Ignites $350 Billion Investment Blitz ↗

September 09, 2025

Trump's policies have sparked a $350B investment surge in US biotech, creating job & revenue opportunities. Investors can track with XBI or IBB ETFs and consider JNJ, NVS, LLY, AZN, BMY as potential...

Via Benzinga

Topics ETFs Government

AstraZeneca Lung Cancer Combo Extends Patient Survival By Years In Key Study ↗

September 08, 2025

AstraZeneca's Tagrisso with chemotherapy improved survival in advanced NSCLC, extending median overall survival by nearly 10 months over monotherapy.

Via Benzinga

Retail Buzz Builds As AstraZeneca’s Tagrisso Combo Extends Lung Cancer Survival To Nearly 4 Years ↗

September 07, 2025

Via Stocktwits

Fibrogen Gets Regulator’s Green Light To Sell China Unit To AstraZeneca ↗

August 18, 2025

Via Stocktwits

Why Dianthus Therapeutics, Up 47% In Four Weeks, Just Surged Again ↗

September 08, 2025

The company is working on a treatment for an autoimmune disease that affects the muscles.

Via Investor's Business Daily

These 2 Healthcare Stocks More Than Doubled Recently and Could Soar Higher, According to Wall Street Analysts ↗

September 07, 2025

Experts who follow these stocks think they can fly higher despite already gaining over 100% since the end of July.

Via The Motley Fool

TAGRISSO® (osimertinib) plus chemotherapy demonstrated a median overall survival of nearly four years, the longest benefit ever reported in a global Phase III trial in EGFR-mutated advanced lung cancer

September 07, 2025

From AstraZeneca

Via Business Wire

AstraZeneca, Corning And More On CNBC's 'Final Trades' ↗

September 04, 2025

On CNBC's “Halftime Report Final Trades,” Jim Lebenthal, partner at Cerity Partners, named AstraZeneca PLC (NASDAQ:AZN) as his

Via Benzinga

Market Jitters: Wall Street Braces for Continued Volatility

September 02, 2025

The U.S. stock market is once again sending signals of caution, as major indices experienced a notable pullback from their recent record highs in early September 2025. This downturn, following a robust...

Via MarketMinute

Topics Artificial Intelligence Bonds Economy

AstraZeneca's Latest Drug Offers Hope For Millions Battling Hard-To-Control Blood Pressure ↗

September 02, 2025

AstraZeneca's Baxdrostat met all endpoints in a Phase 3 trial, showing sustained blood pressure reductions in patients with resistant hypertension.

Via Benzinga

Baxdrostat demonstrated statistically significant and clinically meaningful reduction in systolic blood pressure in patients with hard-to-control hypertension in the BaxHTN Phase III trial

August 30, 2025

From AstraZeneca

Via Business Wire

AstraZeneca's $80 Billion Ambition Just Got A Big Infusion With New Hypertension Results ↗

August 30, 2025

AstraZeneca, on Saturday, unveiled promising results for a new hypertension treatment that aims to help the roughly 650,000 people.

Via Investor's Business Daily

Looking Into AstraZeneca's Recent Short Interest ↗

August 29, 2025

Via Benzinga

Get insights into the top gainers and losers of Tuesday's after-hours session. ↗

August 26, 2025

As the regular session of the US market concludes on Tuesday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses.

Via Chartmill

Regeneron Advances In Rare Disease Race With Positive Autoimmune Muscle Disorder Trial Data ↗

August 26, 2025

Regeneron's Phase 3 NIMBLE trial showed cemdisiran improved myasthenia gravis symptoms, with an FDA filing expected in early 2026.

Via Benzinga

BeOne Cashes In On Amgen's Cancer Drug Royalties In Multibillion-Dollar Pharma Tie-Up ↗

August 25, 2025

BeOne Medicines will sell global Imdelltra royalties to Royalty Pharma for up to $950 million while retaining rights to other oncology programs with Amgen.

Via Benzinga

10 Health Care Stocks With Whale Alerts In Today's Session ↗

August 22, 2025

Via Benzinga

UK Drug Pricing Talks Collapse, Drugmakers Reject Offer Citing 'Uncompetitive' System ↗

August 22, 2025

UK drug pricing talks collapsed after the government and pharma firms failed to agree on National Health Service rebates.

Via Benzinga

J&J Commits $2 Billion To US Manufacturing Expansion Amid Threat Of Drug Tariffs ↗

August 22, 2025

Johnson & Johnson (NYSE: JNJ) is set to invest $2 billion in its North Carolina facilities, expanding its U.S. manufacturing operations. This move comes in response to potential drug import tariffs...

Via Benzinga

Topics Government World Trade

IonQ Expands Quantum IP Portfolio, Surpassing 1,000 Patents And Applications ↗

August 20, 2025

IonQ, Inc. announces major progress in its IP strategy with new U.S. patents, reinforcing its leadership in quantum computing and potential for commercial advantage.

Via Benzinga

Topics Intellectual Property

AstraZeneca Launches Home Delivery Service For Its Self-Administrable Flu Vaccine ↗

August 15, 2025

Flumist can be self-administered by adults 18 to 49 years of age or administered by a parent or caregiver to individuals 2-17 years of age.

Via Stocktwits

FLUMIST (Influenza, Vaccine Live, Intranasal), the nation’s only nasal spray flu vaccine, now available for home delivery

August 15, 2025

From AstraZeneca

Via Business Wire

White House Eyes Up to 250% Drug Tariffs In Bid To Reclaim US Pharma Supply Chain ↗

August 14, 2025

White House trade adviser Peter Navarro discusses tariffs on pharma imports under a "Section 232" trade investigation.

Via Benzinga

Topics World Trade

The Specter of Stagflation: Trump's Tariffs Cast a Long Shadow Over the U.S. Economy

August 11, 2025

Economists and investors are increasingly sounding the alarm over the growing risk of "stagflation," a perilous economic phenomenon characterized by high inflation coupled with stagnant economic...

Via MarketMinute

Topics Economy Government Supply Chain

Sanofi, Eli Lilly, Novo Nordisk, AstraZeneca Face Renewed Claims Of Conspiring To Restrict 340B Discounts ↗

August 11, 2025

A federal appeals court revived a lawsuit accusing Sanofi, Eli Lilly, Novo Nordisk, and AstraZeneca of conspiring to restrict 340B drug discounts for safety-net clinics, sending the case back to...

Via Benzinga

Topics Lawsuit

Stagflation Specter Haunts Markets as Economic Data Disappoints

August 06, 2025

The global financial markets are grappling with a growing sense of unease as recent economic data points to a troubling confluence of high inflation and sluggish growth, rekindling fears of...

Via MarketMinute

Topics Economy Stocks World Trade

1 Small-Cap Biotech Stock Poised for a Breakout ↗

August 06, 2025

This developmental biotech is nearing a key inflection point.

Via The Motley Fool

Topics Economy

Moderna, Pfizer, Sanofi In Focus As US Winds Down mRNA Vaccine Plans; Retail Turns Bearish On AstraZeneca ↗

August 05, 2025

Via Stocktwits

< Previous 1 2 3 4 5 6 7 8 9

...

74 75 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.